Search Results for "Payment"
Research
01/18/2022
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Research
12/20/2021
Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries
Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.
Impact Story
09/01/2021
Savings from drug waste funds a $1.2 trillion infrastructure bill
News
04/09/2021
CMS Announces Delay of MCIT Final Rule
CMS delays the effective date of MCIT rule on "breakthrough" designation after concerns raised by physicians, including Peter Bach.
Person
03/16/2021
Akriti Mishra, MS
Research Biostatistician, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Impact Story
01/06/2021
How a “Netflix Model” Can Help States Pay for Hepatitis C Treatment
Impact Story
11/12/2020
Testifying Before the US Senate Committee on Finance
Research
10/11/2019
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Research
10/11/2019
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
News
01/31/2019
Dr. Bach Testifies at U.S. Senate Committee on Finance's First Hearing of Session
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.
Research
01/29/2019
Overview of Original Subscription Model and Features of LA and WA Proposals
An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.
Research
01/09/2019
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
Our response to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs.
Research
12/17/2018
Fact Checking the NYT Fact Check on the Trump Proposal
The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.
Research
11/16/2018
Expansion of the Medicare 340B Payment Program
As the 340B program expands, it continues to draw national attention.
Research
10/29/2018
The "Netflix Model" of Financing Hepatitis C Treatment
An alternative payment model is proposed to support a population-level payment paradigm.
Research
08/15/2018
Perspective on National Coverage Analysis of CAR-T Therapies
Potential strategies for CMS's evaluation of coverage and payment for the various CAR-T therapies are laid out.
Research
08/01/2018
Spending On Prescription Drugs In The US: Where Does All The Money Go?
Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.
News
05/14/2018
Competitive Acquisition Program
A look at Medicare Part B's Competitive Acquisition Program ahead of President Trump's Blueprint to Lower Drug Prices.
Research
05/02/2018
Value-Based Pricing for Drugs: Theme and Variations
A taxonomy of the features that make a payment model truly value-based.
News
11/03/2017
CMS Changes Payment Policy for Drugs Purchased Through 340B
The Centers for Medicare & Medicaid Services (CMS) finalizes OPPS changes for 2018, including ASP -22.5% for drugs obtained through the 340B program.
News
09/15/2017
DPL Responds to CMS Proposed Changes to OPPS Policy
The Drug Pricing Lab submits a response to CMS-1678-P proposed changes to the Hospital Outpatient Prospective Payment Policy (OPPS).
Research
06/06/2017
Copay Assistance: The Epipen Example
What happens when a patient uses a copay coupon?
Research
05/30/2017
Association of Rebates in Part D with Patient OOP and Federal Spending
The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.
Research
01/04/2017
Hospital Outpatient versus Doctor Office Cost for Physician Administered Cancer Drugs
A new analysis reviews several analyses of differential costs of care provided in the doctors office and hospital outpatient settings.
News
10/12/2016
Drug Coupons: Helping a Few at the Expense of Everyone
Margot Sanger-Katz reports on the negative effects of drug coupons, citing a paper written by Dr. Peter Ubel and Dr. Peter Bach that outlines the issue and prescribes policy solutions.
Research
05/16/2016
Part B Pilot Congressional Concerns
Members of Congress provided conflicting forecasts on how the agency's proposed pilot program of Part B drug payment might affect aspects of Medicare beneficiary care.
Research
04/11/2016
Part B Payment for Medicare Drugs
A new analysis sheds light on why proposed changes to the system are being met with opposition and what they could mean for providers and patients.
News
04/11/2016
This Rule Could Change How Doctors Profit from Using the Most Expensive Drugs
A controversial effort by the Obama administration to reform how doctors earn money from administering injection drugs would reduce their earnings on the most expensive drugs while making many older generics more lucrative.
News
03/10/2016
Medicare Tries an Experiment to Fight Perverse Incentives
Margot Sanger-Katz discusses how doctors are incentivized to prescribe more expensive treatments, and how CMS is devising new payment strategies to combat the practice.
News
03/09/2016
Battle Lines Drawn Over Medicare Pricing Proposal
A new plan would seek to change practice of paying doctors more for prescribing higher-priced drugs.
No Results Found